Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

The global Heart Failure Drugs Market is valued at $8.6 billion in 2024 and is projected to reach a value of $21.4 billion by 2035. This growth represents a Compound Annual Growth Rate (CAGR) of 12.1% ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Amgen Inc.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...